SERB Pharmaceuticals strengthens leadership in medical countermeasures with the global acquisition of RSDL® (Reactive Skin Decontamination Lotion) kit for $75 million
2024年7月31日 - 10:06PM
SERB Pharmaceuticals, a global specialty pharmaceutical company,
announced today the acquisition of RSDL® (Reactive Skin
Decontamination Lotion) kit from Emergent BioSolutions Inc. (NYSE:
EBS) for an up-front payment of approximately $75 million. In
addition, SERB will pay Emergent a $5 million payment upon first
achievement of a milestone relating to sourcing of certain
components of RSDL®. As part of the transaction, SERB will also
acquire and maintain the operation of the leased manufacturing
facility in Hattiesburg, Mississippi and several employees who
support the site and RSDL® product will join SERB.
RSDL® is a medical device provided as a kit, with a lotion
impregnated sponge in a packet, intended to remove or neutralize
chemical warfare agents from the skin. RSDL removes or neutralizes
chemical warfare agents (CWAs) including: tabun, sarin, soman,
cyclohexyl sarin, VR, VX, mustard gas, and T-2 toxin. RSDL®
is the only FDA-cleared device backed by 20 years of clinical data,
that can remove or neutralize chemical warfare agents from the skin
in one step. Over 15 million packets of RSDL® have been sold
in over 30 countries.
“The acquisition of RSDL® strengthens our position as the
leading provider of medical countermeasures for chemical,
biological, radiological and nuclear threats," said Jeremie Urbain,
Chairman of SERB Pharmaceuticals. “Alongside our broad portfolio of
antidotes and preventive medicines, RSDL® will give SERB new
opportunities to support and partner with governments, militaries,
NGOs and emergency preparedness agencies around the world.”
RSDL® was initially developed by Defence Research and
Development Canada, an agency of the Canadian Department of
National Defence, to prepare the Canadian forces for chemical
warfare attacks. RSDL® was 510(k) cleared by the FDA in 2003 and
was subsequently issued a European CE Mark, and approval by Health
Canada, the Australian Therapeutic Goods Administration and Israeli
Ministry of Health.
Rothschild served as financial advisor to SERB and Freshfields
served as legal counsel to SERB in connection with the
transaction.
About SERB Pharmaceuticals
SERB is a global specialty pharmaceutical company with a growing
portfolio of medicines for emergency care and rare diseases. For
over 30 years we have made treating these complex and
life-threatening conditions possible, supporting clinicians,
healthcare systems and governments while offering hope to patients
and their families. SERB has the broadest antidote portfolio in the
world, including medical countermeasures for chemical, biological,
radiological and nuclear (CBRN) risks. As a fully integrated
company, we have the experience and capabilities to acquire,
develop, and manufacture our medicines to the highest standards,
and make them available worldwide through our secure supply chain.
Learn more at https://SERB.com.About RSDL® (Reactive
Skin Decontamination Lotion)
Indication The Reactive Skin Decontamination
Lotion is intended to remove or neutralize chemical warfare agents,
and T-2 Toxin from the skin.
Important Safety InformationRSDL® is for
external use only. It should be used only if chemical warfare agent
exposure is suspected and as directed. It is not for prophylactic
use or whole body decontamination. An RSDL® ingredient is absorbed
through the skin and may cause adverse effects. Prolonged skin
contact and contact with the eyes and mucous membranes must be
avoided. RSDL® may cause skin irritation and should be removed when
conditions permit.
Chris Sampson
SERB Pharmaceuticals
+44 7773 251 178
chris.sampson@serb.com